BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1167 related articles for article (PubMed ID: 22703879)

  • 1. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes.
    Johnston JJ; Rubinstein WS; Facio FM; Ng D; Singh LN; Teer JK; Mullikin JC; Biesecker LG
    Am J Hum Genet; 2012 Jul; 91(1):97-108. PubMed ID: 22703879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actionable, pathogenic incidental findings in 1,000 participants' exomes.
    Dorschner MO; Amendola LM; Turner EH; Robertson PD; Shirts BH; Gallego CJ; Bennett RL; Jones KL; Tokita MJ; Bennett JT; Kim JH; Rosenthal EA; Kim DS; ; Tabor HK; Bamshad MJ; Motulsky AG; Scott CR; Pritchard CC; Walsh T; Burke W; Raskind WH; Byers P; Hisama FM; Nickerson DA; Jarvik GP
    Am J Hum Genet; 2013 Oct; 93(4):631-40. PubMed ID: 24055113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.
    Ellingson MS; Hart SN; Kalari KR; Suman V; Schahl KA; Dockter TJ; Felten SJ; Sinnwell JP; Thompson KJ; Tang X; Vedell PT; Barman P; Sicotte H; Eckel-Passow JE; Northfelt DW; Gray RJ; McLaughlin SA; Moreno-Aspitia A; Ingle JN; Moyer AM; Visscher DW; Jones K; Conners A; McDonough M; Wieben ED; Wang L; Weinshilboum R; Boughey JC; Goetz MP
    Breast Cancer Res Treat; 2015 Sep; 153(2):435-43. PubMed ID: 26296701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
    Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
    Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing.
    Bodian DL; McCutcheon JN; Kothiyal P; Huddleston KC; Iyer RK; Vockley JG; Niederhuber JE
    PLoS One; 2014; 9(4):e94554. PubMed ID: 24728327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exome Sequencing Identifies a Novel LMNA Splice-Site Mutation and Multigenic Heterozygosity of Potential Modifiers in a Family with Sick Sinus Syndrome, Dilated Cardiomyopathy, and Sudden Cardiac Death.
    Zaragoza MV; Fung L; Jensen E; Oh F; Cung K; McCarthy LA; Tran CK; Hoang V; Hakim SA; Grosberg A
    PLoS One; 2016; 11(5):e0155421. PubMed ID: 27182706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
    Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
    Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
    Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
    Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.
    Maxwell KN; Hart SN; Vijai J; Schrader KA; Slavin TP; Thomas T; Wubbenhorst B; Ravichandran V; Moore RM; Hu C; Guidugli L; Wenz B; Domchek SM; Robson ME; Szabo C; Neuhausen SL; Weitzel JN; Offit K; Couch FJ; Nathanson KL
    Am J Hum Genet; 2016 May; 98(5):801-817. PubMed ID: 27153395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
    BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-Based Penetrance of Deleterious Clinical Variants.
    Forrest IS; Chaudhary K; Vy HMT; Petrazzini BO; Bafna S; Jordan DM; Rocheleau G; Loos RJF; Nadkarni GN; Cho JH; Do R
    JAMA; 2022 Jan; 327(4):350-359. PubMed ID: 35076666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The implications of familial incidental findings from exome sequencing: the NIH Undiagnosed Diseases Program experience.
    Lawrence L; Sincan M; Markello T; Adams DR; Gill F; Godfrey R; Golas G; Groden C; Landis D; Nehrebecky M; Park G; Soldatos A; Tifft C; Toro C; Wahl C; Wolfe L; Gahl WA; Boerkoel CF
    Genet Med; 2014 Oct; 16(10):741-50. PubMed ID: 24784157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ; Bewtra C
    Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.
    Li N; Rowley SM; Thompson ER; McInerny S; Devereux L; Amarasinghe KC; Zethoven M; Lupat R; Goode D; Li J; Trainer AH; Gorringe KL; James PA; Campbell IG
    Breast Cancer Res; 2018 Jan; 20(1):3. PubMed ID: 29316957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-exome sequencing identifies rare genetic variations in German families with pulmonary sarcoidosis.
    Kishore A; Petersen BS; Nutsua M; Müller-Quernheim J; Franke A; Fischer A; Schreiber S; Petrek M
    Hum Genet; 2018 Sep; 137(9):705-716. PubMed ID: 30054724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
    Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
    BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exome sequencing identifies potential risk variants for Mendelian disorders at high prevalence in Qatar.
    Rodriguez-Flores JL; Fakhro K; Hackett NR; Salit J; Fuller J; Agosto-Perez F; Gharbiah M; Malek JA; Zirie M; Jayyousi A; Badii R; Al-Nabet Al-Marri A; Chouchane L; Stadler DJ; Mezey JG; Crystal RG
    Hum Mutat; 2014 Jan; 35(1):105-16. PubMed ID: 24123366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
    Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
    JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.